Table 1.
Clinical Characteristics of the Obese Women Studied
| Variables | Obese Women (n=62) |
|---|---|
| Age (years)a | 39.53±8.99 |
| Weight (kg)a | 108.6±13.86 |
| BMI (kg/m2)a | 42.6±4.64 |
| Marital status (married), % (n) | 50 (31) |
| Level of schooling, % (n) | |
| University | 40.32 (25) |
| Incomplete university | 9.67 (6) |
| High school | 24.19 (15) |
| <High school | 25.8 (16) |
| Arterial hypertension, % (n) | 53.22 (33) |
| Type 2 diabetes mellitus, % (n) | 24.19 (15) |
| Current smoking, % (n) | 0 |
| Physical activity, % (n) | 53.22 (33) |
| Moderate physical activity ≥ 150 min/week, % (n) | 40 (25) |
| Nutritional counselling, % (n) | 66 (41) |
| Dyslipidemia, % (n) | 38.7 (24) |
| Menopause, % (n) | 20 (12) |
| Atraumatic bone fracture, % (n) | 0 |
| Antiglycemics, % (n) | |
| Biguanides | 21 (33.8) |
| SGLT-2 inhibitors | 4.83 (3) |
| Thiazolidinediones | 1.61 (1) |
| DPP-4 inhibitors | 1.61 (1) |
| GLP-1 analogs | 1.61 (1) |
| Insulin | 6.45 (4) |
| Antihypertensive, % (n) | |
| ARBII | 29 (18) |
| ACE I inhibitors | 12.9 (8) |
| β-Blocker | 8 (5) |
| Calcium blockers | 6.45 (4) |
| Diuretics | 25.8 (16) |
| Obesity medications, % (n) | 38.7 (24) |
| Dual-energy X-ray absorptiometry, % (n) | |
| Postmenopausal women | |
| Osteopenia | 8 (5) |
| Osteoporosis | 0 |
| Premenopausal women | |
| Low bone mass | 0 |
Note: aData are expressed as mean ± standard deviation.
Abbreviations: BMI, body mass index; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-Like Peptide-1 analogs; ARBII, angiotensin II receptor antagonists; ACEI, angiotensin-converting enzyme I inhibitors.